These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8768829

  • 1. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution.
    Derwahl M.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2783-5. PubMed ID: 8768829
    [Abstract] [Full Text] [Related]

  • 2. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas.
    Derwahl M, Hamacher C, Russo D, Broecker M, Manole D, Schatz H, Kopp P, Filetti S.
    J Clin Endocrinol Metab; 1996 May; 81(5):1898-904. PubMed ID: 8626855
    [Abstract] [Full Text] [Related]

  • 3. Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms.
    Derwahl M, Manole D, Sobke A, Broecker M.
    Exp Clin Endocrinol Diabetes; 1998 May; 106 Suppl 4():S6-9. PubMed ID: 9867188
    [Abstract] [Full Text] [Related]

  • 4. Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas.
    Derwahl M.
    Exp Clin Endocrinol Diabetes; 1996 May; 104 Suppl 4():32-5. PubMed ID: 8980997
    [Abstract] [Full Text] [Related]

  • 5. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
    Tonacchera M, Chiovato L, Pinchera A, Agretti P, Fiore E, Cetani F, Rocchi R, Viacava P, Miccoli P, Vitti P.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):492-8. PubMed ID: 9467563
    [Abstract] [Full Text] [Related]

  • 6. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
    Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, Costagliola S, Rodien P, Dumont JE, Vassart G.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356
    [Abstract] [Full Text] [Related]

  • 7. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
    Paschke R.
    Exp Clin Endocrinol Diabetes; 1996 Aug; 104 Suppl 4():129-32. PubMed ID: 8981020
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism].
    Derwahl M.
    Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():25-8. PubMed ID: 10355046
    [Abstract] [Full Text] [Related]

  • 12. Low incidence of the stimulatory G protein alpha-subunit mutations in autonomously functioning thyroid adenomas in Japan.
    Tanaka K, Nagayama Y, Takeshita A, Namba H, Yamashita S, Niwa M, Nagataki S.
    Thyroid; 1996 Jun; 6(3):195-9. PubMed ID: 8837326
    [Abstract] [Full Text] [Related]

  • 13. [Molecular aspects in the pathogenesis of nodules and adenomas of the thyroid gland].
    Derwahl M.
    Schweiz Med Wochenschr; 1994 Sep 17; 124(37):1613-8. PubMed ID: 7939528
    [Abstract] [Full Text] [Related]

  • 14. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter.
    Tonacchera M, Agretti P, Chiovato L, Rosellini V, Ceccarini G, Perri A, Viacava P, Naccarato AG, Miccoli P, Pinchera A, Vitti P.
    J Clin Endocrinol Metab; 2000 Jun 17; 85(6):2270-4. PubMed ID: 10852462
    [Abstract] [Full Text] [Related]

  • 15. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil.
    Nogueira CR, Kopp P, Arseven OK, Santos CL, Jameson JL, Medeiros-Neto G.
    Thyroid; 1999 Nov 17; 9(11):1063-8. PubMed ID: 10595453
    [Abstract] [Full Text] [Related]

  • 16. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation.
    Spambalg D, Sharifi N, Elisei R, Gross JL, Medeiros-Neto G, Fagin JA.
    J Clin Endocrinol Metab; 1996 Nov 17; 81(11):3898-901. PubMed ID: 8923835
    [Abstract] [Full Text] [Related]

  • 17. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
    Parma J, Van Sande J, Swillens S, Tonacchera M, Dumont J, Vassart G.
    Mol Endocrinol; 1995 Jun 17; 9(6):725-33. PubMed ID: 8592518
    [Abstract] [Full Text] [Related]

  • 18. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid.
    Paschke R, Tonacchera M, Van Sande J, Parma J, Vassart G.
    J Clin Endocrinol Metab; 1994 Dec 17; 79(6):1785-9. PubMed ID: 7989485
    [Abstract] [Full Text] [Related]

  • 19. Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene.
    Polak M.
    Arch Med Res; 1999 Dec 17; 30(6):510-3. PubMed ID: 10714365
    [Abstract] [Full Text] [Related]

  • 20. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations.
    Krohn K, Führer D, Holzapfel HP, Paschke R.
    J Clin Endocrinol Metab; 1998 Jan 17; 83(1):130-4. PubMed ID: 9435429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.